# Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

Study · id `cardio:ct-nct06037889` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06037889](<https://clinicaltrials.gov/study/NCT06037889>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06037889

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 516 participants.

## Technical summary

Registry record NCT06037889. Randomized; single masking; primary purpose treatment. Start 2023-11-09 (actual); primary completion 2026-02-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 516 participants (enrolled count; ClinicalTrials.gov record NCT06037889, source copy `cardio:ctgov-nct06037889-2026-04-15`, retrieved 2026-10-26)
- Started: 2023-11-09 (actual) (ClinicalTrials.gov record NCT06037889, source copy `cardio:ctgov-nct06037889-2026-04-15`, retrieved 2026-10-26)
- Primary completion: 2026-02-26 (actual) (ClinicalTrials.gov record NCT06037889, source copy `cardio:ctgov-nct06037889-2026-04-15`, retrieved 2026-10-26)
- Completion: 2026-02-26 (actual) (ClinicalTrials.gov record NCT06037889, source copy `cardio:ctgov-nct06037889-2026-04-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06037889, source copy `cardio:ctgov-nct06037889-2026-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06037889-2026-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
- Acronym: BRANT
- Condition: Branch Atheromatous Disease
- Intervention (Drug): Tirofiban
- Intervention (Drug): Aspirin tablet
- Intervention (Drug): Clopidogrel tablet
- Lead sponsor: Peking Union Medical College Hospital
- Lead sponsor class: OTHER
- Collaborator: Pharmaron (Chengdu) Clinical Services Co., Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Peking Union Medical College Hospital (`cardio:org-peking-union-medical-college-hospital`)

## Provenance

Content hash: d5949b2db7f07505780f1c13b6716cdf73cac7b66096b1c7b97e7ccd9582e4e7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
